NeoStem to present at three conferences in October

NeoStem (NYSE:NBS), a biopharmaceutical company focused on developing cell-based therapies, said on Tuesday that its Progenitor Cell Therapy unit will present at three conferences in the U.S.
The World Stem Cell Summit, the first conference, will be held on October 3 to 5 in Pasadena, California at the Convention Centre.
NeoStem’s VP of strategic business development Jason Kolbert will talk about the paradigm shift to cell-based medicine and how investors can discern value, today at 3:45 p.m.
Chairman and CEO Robin Smith will also speak at the summit on Wednesday at 12 p.m., discussing the financing pathways for stem cell companies and new funding options.
Further, the second conference, Cell Therapy Bioprocessing, will be held on October 17 to 18 at the Hyatt Regency Reston, in Virginia.
Presenting on Monday, October 17 will be Progenitor’s Director Karen Trujillo, where she will talk about product development.
In a statement, NeoStem’s CEO Smith said: "We consider this event an excellent platform to speak about our business lines. NeoStem endeavors to be an integrative force in the cell therapy industry."
Finally, the third conference, AABB Annual Meeting & CTTXPO, is scheduled for October 22 to 25 at the San Diego, California Convention Centre.
Progenitor Cell Therapy’s president and chief scientific officer Robert Preti will discuss cellular therapy product development using project management techniques on Saturday, October 22, at 10:30 a.m.
Preti noted: "Progenitor Cell Therapy is excited to have these venues in the coming month to demonstrate our leadership in cell therapy development, manufacturing, quality assurance, regulatory consulting, and more."
NeoStem, with operations in China and the U.S., is focused on developing cellular therapies and becoming a source for the collection, storage, manufacturing and transportation of stem cells. It also has a 51% interest in a Chinese generic pharmaceutical manufacturing company.